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Low back pain (LBP) is the most common orthopedic complaint managed by 
physical therapists in the United States. Insurance plans that require greater patient 
financial liability per physical therapy visit are thought to disincentivize participation in 
recommended physical therapy plans of care. The primary purpose of this investigation 
was to use instrumental variable regression to investigate the effect of insurance-
mediated patient financial liability per visit on physical therapy visit count and functional 
patient reported outcomes. The secondary purpose of the study was to examine the 
generalizability of results to the broader excluded patient population—and beyond to 
patients that seek physical therapy for LBP. Insurance-mediated patient financial liability 
per visit was a poor instrument with an inconsistent effect that trended against the 
hypothesized direction. The instrument had no statistically or clinically important effect 
on visit count, and no subsequent clinically important change in patient reported 
outcome. A comparison of baseline patient information and “index” values for predicted 
visit count and change in patient reported outcome identified few potential clinically 
important differences, yielding the conclusion that results of the primary investigation are 
likely generalizable to a broader patient population with LBP. These results suggest 
patient financial liability per visit is a poor instrument with currently available data; 
however, any results from large observational analyses would likely generalize to a larger 
patient population with LBP.  
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Introduction & Review of Literature
Background 
Low back pain (LBP) is the most common orthopedic complaint in the United 
States (U.S.) with an estimated lifetime prevalence of 80%.1 Evidence-based guideline 
care recommendations have been introduced to promote clinically and cost-effective 
management—and reduce costly, unwarranted variation in the evaluation and 
management of patients seeking medical care for LBP.2,3 Early care guidelines co-
endorsed by the American College of Physicians and the American Pain Society in 2007 
promoted screening for psychological risk-factors known to influence the development of 
chronic LBP and a thorough physical exam that categorized patients into defined 
classification groups to help guide appropriate interventions.2 These guidelines also 
strongly endorsed limited use of imaging (i.e., x-rays, computed tomography [CT], and 
magnetic resonance imaging [MRI]), limited use of over the counter medication (i.e., 
acetaminophen, non-steroidal anti-inflammatory drugs [NSAIDS]), and promoted patient 
education that encouraged appropriate self-care, maintaining an active lifestyle, and an 
understanding of the expected course of their condition.2 More recently, guideline 
recommendations co-endorsed by the American College of Physicians and American 
Academy of Family Physicians in 2017 recommended classifying patients as 
acute/subacute or chronic—then provided evidence-based, non-invasive treatment 
recommendations for each classification.3 For patients with acute or subacute LBP, 
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superficial heat, massage, acupuncture, spinal manipulation, NSAIDS, and skeletal 
muscle relaxants were recommended; while exercise, multidisciplinary rehabilitation, 
acupuncture, mindfulness, Tai Chi, yoga, motor control exercise, progressive relaxation, 
electromyography biofeedback, low-level laser therapy, cognitive behavioral therapy, 
spinal manipulation, limited use of NSAIDS and prescription drugs such as Tramadol and 
Duloxetine, and prescription opioids as a last resort were recommended for patients with 
chronic LBP.3 While providers are not expected to apply or recommend all described 
intervention strategies, they are expected to routinely incorporate these evidence-based 
care approaches for their patients with LBP. 
Knowledge Gap 
These care recommendations are routinely applied in the physical therapy 
settings.4 However, there are mixed results when examining health outcomes in patients 
receiving treatment from these ancillary health providers.5-15 Heterogeneity of treatment 
effect related to patients’ attitudes, beliefs, willingness to participate in and pay for 
healthcare, and predisposition to respond to care likely contribute to these muted 
effects—but differences in clinical effectiveness and expertise of the providers may also 
contribute.16-20 
Patient reported outcomes (PROs) are commonly used as the primary health 
outcome in orthopaedic physical therapy clinical and research settings.16,17,21-33 In 
research settings, it is important to consider how a PRO is used. Comparative 
effectiveness researchers typically opt to examine change in the PRO from the index date 
(i.e. initial date of complaint) through final evaluation.34 Other potential options include 
identification of a PRO “cut score” that equates to “success” or “failure” or using the 
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final or discharge PRO as a numeric outcome. PROs provide the healthcare provider and 
researcher with valuable information regarding patient perception of their health 
condition, and the effect of treatment on their function and/or health status.35 
Many PROs are used for the management and study of patients with LBP. 
Commonly used PROs for patients with LBP include the Oswestry Disability Index 
(ODI) and its modification—the Modified Low Back Pain Disability Questionnaire 
(MDQ), Roland-Morris Disability Questionnaire (RMDQ), and Quebec Back Pain 
Disability Scale (QBPDS).22,36-38 The ODI and its modification, the MDQ, represent the 
most commonly used PROs for patients with LBP in the outpatient physical therapy 
setting.32 ATI Physical Therapy utilizes the MDQ and represents the primary data source 
for this investigation (detailed below); therefore, greater detail specific to the MDQ 
follows. The MDQ is a functional status, condition-specific PRO for patients with LBP 
that consists of 10 questions.22,39 Responses range from 0 (no disability) to 5 (maximal 
disability) for each question yielding a total of 50 potential “raw” points (higher score = 
greater disability).22 This value is then doubled to identify a “percent disability” related to 
the lower back for a patient. Pertinent statistical properties of the MDQ to consider 
include standard error of the measure (SEM), minimal detectable change (MDC), 
minimal clinically important difference (MCID), Cronbach’s alpha, and intraclass 
correlation coefficient (ICC). As the MDQ is a modified version of the original ODI, few 
studies have examined its statistical properties separately from the original ODI. Fritz and 
Irrgang22 reported an SEM of 5.4, MDC of 12.7, MCID of 6, and ICC of 0.9 specific to 
the MDQ, while more recent work identified an MCID of 10.8.40 While one condition-
specific (i.e., pelvic girdle pain) study examined Cronbach’s alpha for the MDQ, none 
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have reported these values in a general population with LBP.41 Fritz and Irrgang22 
concluded that the MDQ had better measurement properties than the QBPDS. Resnik and 
Dobrzykowski24 identified comparable statistical properties for the ODI and its 
modifications (including MDQ) and the RMDQ and concluded that either are reasonable 
for use in outcomes research involving patients with LBP.  
It has been demonstrated that change in MDQ is influenced by initial MDQ, 
initial Veteran’s RAND 12-Item Health Survey (VR-12) Mental (MCS) and Physical 
(PCS) component scores, age, sex, body mass index (BMI), comorbid conditions reported 
on a baseline health history, state of physical therapy services, payer status, status as 
chronic condition, and ZIP-level median income.16,22,42 The VR-12 is a general health 
survey with both mental and physical component scores as highlighted above.43 It is a 
norm-based standardized outcome that allows the investigator to control for health status 
relative to a population-based distribution for each component scoer.42 While not specific 
to change in MDQ, baseline objective clinical measures, exercise history, surgical 
history, specific diagnoses, clinical presentation (i.e., LBP with pain below knee), clinic 
level characteristics (e.g., referral source, number of referrals), employment status, 
provider equipoise, patient and provider beliefs and preferences, and fear-avoidance have 
also been identified or theorized as factors that influence change in PROs.15,17,25,27-29,44 
Finally, it is theorized that the number of physical therapy visits attended relative to a 
hypothetical ‘optimal’ amount has an influence on PRO change. Figure 1.1 highlights 
these factors known or theorized to influence PRO change. 
While the number of physical therapy visits attended is a factor theorized to 
influence PRO change, it is also an outcome—with several factors known or theorized to 
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influence its utilization. As an outcome, it offers the investigator flexibility in research 
design, opportunities to perform multiple comparisons to corroborate findings, and the 
ability to make more accurate assessments of the risks associated with treatment(s).45 
Factors known or theorized to influence physical therapy visit count (Figure 1.2) include 
initial disability, health insurance generosity or plan generosity, prior health seeking 
behaviors, access to care, socioeconomic status, health status, patient and provider 
beliefs, surgical history, and provider supply.46-54 While objective, healthcare claims and 
utilization information are not captured for research purposes, intended instead for billing 
and reimbursement. These data sources can lack detail that would be important to the 
researcher and therefore limit the inferences that can be made.55 
Healthcare utilization as a health outcome can be used broadly to observe health 
trends or with more granularity to provide clinical context and inform policy. Using 
healthcare utilization as an outcome is beneficial because it is often associated with large 
sample sizes pulled from health system or insurance databases.45 It is also void of patient 
factors that can introduce bias such as recall or refusal to participate.56,57 Additionally, 
while healthcare utilization is sometimes used as a proxy for health status, there is no 
clear association between healthcare utilization and PROs.58 Rundell et al59 explored this 
idea peripherally and found that physical therapy service utilization of active and manual 
interventions were associated with self-reported pain and there was a threshold for 
utilization of these services associated with improved PROs—but there was no linear 
relationship between the two. Furthermore, predictors of change in PROs often differ 
from predictors of healthcare utilization.16,17,27-29,50 Finally, this relationship is likely 
mediated in some way by insurance attributes that affect a patient’s financial liability for 
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treatment.21,60 It is reasonable to believe, therefore, that this assumption has limitations 
and these relationships should be further investigated. 
Theoretical & Methodological Framework 
Little is understood regarding the interrelationships between patient factors, 
healthcare evaluation and management, patient financial responsibility per physical 
therapy visit, and healthcare utilization and PROs. Donabedian61 called health outcomes 
the “ultimate validators of the effectiveness and quality of medical care”. Health 
outcomes, including PROs, are often missing in these ‘real world’ research designs, 
leading investigators to explain away the missingness and its effect on validity and 
generalizability.62-64 While problematic for PROs collected prospectively in a controlled 
research setting, the challenge of PRO missingness can be magnified when examining 
secondarily obtained observational data from electronic health records (EHRs) and health 
databases. Patient reported outcomes derived from EHRs are often used in orthopaedic 
physical therapy research to test the effectiveness of interventions and 
therapists.9,16,17,24,25,27-30,33,34 There is wide variation in collection of follow-up PROs 
across the rehabilitation industry, and little is understood regarding the appropriate 
handling of these missing outcomes and the impact of missingness on generalizability of 
results.16,17,25,27,29,30 
Instrumental variable (IV) regression is an observational research approach that 
exploits natural variation to allow causal inference.65-67 It utilizes a two-stage least 
squares (2SLS) approach in which the first stage regresses all baseline explanatory 
variables (i.e., baseline demographic and outcome information) and exogenous IVs to 
estimate the treatment choice (i.e., physical therapy visit utilization), and the second stage 
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regresses all baseline explanatory variables AND first stage outcome(s) to estimate the 
healthcare utilization outcomes defined below.66,67 Estimates derived from IV estimators 
can therefore be generalized to a “marginal” subset of patients whose treatment choices 
are influenced by the instrument.66 
Instrumental Variables are variables theorized to impact treatment choice but 
have no impact on the outcome of treatment.67,68 Harris and Remler69 highlight 4 
conditions a variable must meet for consideration as a valid instrument. The candidate IV 
must: 1) influence probability of treatment, 2) not independently effect change in the 
outcome of interest, 3) not be influenced by health status or health outcomes 
(exogeneity), and 4) only influence the probability of treatment in one direction 
(monotonicity). Health insurance plan-level patient financial liability per visit was 
considered as the candidate IV. Health insurance plan generosity was theorized to 
influence treatment choice by incentivizing more physical therapy visits. Additionally, 
there was no direct theorized influence of insurance plan-level patient financial liability 
per visit and PRO change—aside from its effect via visit count. Finally, because it was 
aggregated to the insurance level mean, the IV was exogenous to any 1 patient. 
Research Questions 
1. What is the influence of insurance-level patient financial liability per visit on 
physical therapy visits and episodic patient reported outcomes in commercially 
and Medicare-insured patients? 
The purpose of this investigation was to evaluate the influence of insurance-
mediated patient financial liability per visit on physical therapy visit count and PRO 
change. Commercially-insured patients 18 – 64 years of age that received physical 
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therapy for “nonoperative” LBP at ATI Physical Therapy across 26 states in the U.S. 
between January 1, 2017 and December 31, 2018 were considered for inclusion. 
“Nonoperative” LBP was defined for this Research Question as LBP with no self-
reported surgical intervention related to the lumbar spine within 120 days prior to initial 
physical therapy evaluation. Baseline patient demographic information, initial and final 
MDQ outcomes, health insurance-level patient financial liability per visit, and physical 
therapy billing and utilization information for all patients were extracted from the ATI 
Physical Therapy Patient Outcomes Registry. 
The patient financial liability per physical therapy visit averaged across an 
insurance plan was the candidate IV for Research Question 1. While a portion of patients 
in this sample may have sought out employment opportunities or an insurance market 
insurance plan specifically related to their anticipated musculoskeletal health needs, the 
assumption for this investigation is that the vast majority of patients did not select 
insurance benefits specific to expected impact on the management of LBP. Further, by 
using the aggregated insurance plan-level mean and requiring a minimum patient count 
per plan, the patient financial liability per visit was exogenous to any 1 patient in the 
insurance plan and observed variation is this metric provided a natural experiment for 
testing. 
Of the independent variables known or theorized to impact PRO change and 
physical therapy visit utilization described above, those measurable in the ATI Physical 
Therapy Patient Outcomes Registry were initial MDQ, initial VR-12, sex, age, body mass 
index (BMI), time from onset to initial physical therapy evaluation dichotomized as acute 
or chronic (>=90 days), patient ZIP-level median annual income as a proxy for 
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socioeconomic status (SES), and comorbid conditions per patient-reported medical 
history.16,17,27,28,42 The first stage regression equation regressed all independent variables 
and the candidate IV on the number of physical therapy visits observed in the episode of 
care between initial and final MDQ. The second stage regression equation regressed all 
independent variables and the first stage predicted value (i.e., number of physical therapy 
visits in the episode of care) on the terminal outcome, MDQ change. 
This methodology allows for careful inferences to be made regarding PROs in 
marginal patients for whom treatment choice (i.e., number of physical therapy visits) is 
affected by patient financial liability per visit. It is hypothesized that these marginal 
patients will achieve clinically important benefit (i.e., greater PRO change) for choosing 
to attend more physical therapy visits. 
Limitations 
Limitations to this research approach should be considered. First, data for this 
research question was obtained for commercially insured patients from a group of 
physical therapy clinics owned by the same company (ATI Physical Therapy). 
Accordingly, results may not generalize to other payer types or physical therapy 
providers. Second, patient financial liability may not be a strong enough instrument to 
significantly influence the number of physical therapy visits a patient attends. While the 
study controls for ZIP-level SES, individual SES and specific insurance plan structure 
were unknown and likely drive healthcare utilization to a greater extent than is 
observable when examining the effects of patient financial liability. Further, recent 
evidence suggests that high deductible health insurance plans have a similar effect on 
physical therapy utilization as health insurance plans with much lower deductibles.47 
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High deductible plans with employer or employee tax deductible savings accounts may 
be more willing to take on the risk associated with greater financial liability associated 
with their healthcare. The interaction between socioeconomic status and plan design is 
also likely a contributing factor as wealthy beneficiaries have been demonstrated to self-
select to high deductible, health savings account-styled plans given their added ability to 
take on the associated financial risk.70 Third, the MDQ may be insufficiently 
discriminatory as the terminal outcome of interest—yielding results that are not 
statistically, or more importantly clinically significant.22,36 Finally, additional unknown 
and unmeasured confounding may remain due to the lack of predictability associated with 
physical therapy outcomes—leading to biased estimates.16,17,30 
Delimitations 
Consistent with the stated limitations of the study, the results of this analysis are 
generalizable only to commercially-insured patients 18 – 64 years of age with 
nonoperative LBP that receive physical therapy for their complaint under the care of a 
large, unified physical therapy provider. Furthermore, conclusions only apply to marginal 
patients impacted by the patient financial liability for physical therapy visits as dictated 
by their insurance policy. Although it is not feasible to directly identify whom these 
marginal patients are a priori, precedent comparisons have been made between quintiles 






2. What is the influence on missingness and loss to follow-up in physical therapy 
outcomes research? 
Research endeavors often take place in a ‘real world’ environment to improve 
available sample and maximize generalizability.16,17,27-29,52,72,73 The United States 
Department of Health and Human Services has defined comparative effectiveness 
research (CER) as research that compares “the benefits and harms of different 
interventions and strategies to prevent, diagnose, treat and monitor health conditions in 
“real world” settings.”74 Further, it aims to clarify the effectiveness of established health 
interventions.75  
Because “real world” health information and pragmatic research approaches often 
lack data, we desired to better understand how generalizable the inferences made on the 
“complete cases” was to the broader, less complete patient population. As a 
representative sample, Research Question 1 required the inclusion of several distinct data 
sets, limiting the included sample significantly. The purpose of Research Question 2 was 
to thoroughly vet baseline patient information and patient reported outcomes (PROs) to 
establish a level of confidence for the generalizability of results to the broader physical 
therapy patient population. Available evidence suggests that baseline patient information 
accounts for less than 40% of the variability in PRO change. Despite this limitation in 
predictive ability, if known baseline information for the included and excluded cohorts of 
patients were comparable, our confidence in the generalizability of the results and 
inferences would improve.16,17,30 We hypothesized that these baseline values would 
indeed be comparable, and the inferences made would generalize well to the broader 
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patient population—understanding that limitations remain, given the unexplained 
variability. 
Limitations 
Like the approach for Research Question 1, the data used for this investigation 
were observational, secondarily obtained data collected for billing purposes and not 
intended to be used for research. While commercially insured patients with LBP 
accounted for approximately 55% of the ATI Physical Therapy patient population, 
inferences were limited to those payer groups. Finally, as ATI Physical Therapy is a 
single, unified company, results may be related to unique proprietary behaviors and a 
strict interpretation would generalize only to their patients. 
Delimitations 
The results of Research Question 2 informed generalizability of Research 
Question 1 to the broader commercial-insured patient population—including those that 
failed to complete following PROs. Chapters 4 and 5 offer an extended discussion of 
delimitations as this is the focus of Research Question 2. 
Data Integrity and Security 
Data integrity and security was vital and well-maintained throughout the 
investigations. A data use agreements (DUA) was in place prior to the transfer of data 
between entities. Patient information provided by ATI Physical Therapy was transferred 
securely from within the ATI Physical Therapy Health Insurance Portability and 
Accountability Act (HIPAA) certified server to the South Carolina Center for 
Effectiveness Research in Orthopaedics (SC CEROrtho) HIPAA-certified server using an 
existing Secure File Transfer Protocol. All policies and procedures set forth by the DUA 
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were followed. This investigation was approved by the University of South Carolina 
Institutional Review Board (Pro00090115). 
Conclusion 
The two aims fill important gaps in musculoskeletal health and physical therapy 
literature. While it is logical that insurance plans with higher patient financial liability 
influence patients to attend fewer physical therapy visits—and that those with fewer visits 
for the same condition have poorer PROs at discharge, this complex relationship has not 
been thoroughly tested. Second, at a time when the clinical quality and effectiveness is 
increasingly important with the rise of value-based reimbursement, it was important to 
have a better understanding of the importance of missingness and its effect on 
generalizability in physical therapy outcomes research. 
 









Research Design: Overview 
The overall goal of this study was to evaluate the role of patient financial liability 
per visit on patient reported outcomes (PROs) and physical therapy visit utilization. 
Research Question 1 used an instrumental variable (IV) regression approach to examine 
the influence of insurance-level patient financial liability per visit on physical therapy 
utilization and PROs for patients that received care from a single, national physical 
therapy provider. Research Question 2 explored the generalizability of results to the 
cohort of excluded patients from Research Question 1. Observational research methods 
were used in an attempt to fill important gaps in the literature regarding the association 
between health insurance plans, physical therapy visit utilization, and PRO change for 
patients with low back pain (LBP). Statistical computations were performed using R 
within a Health Insurance Portability and Accountability Act (HIPAA) secure server.76 
The studies followed the REporting of studies Conducted using Observational Routinely 
collected Data initiative and was approved by The University of South Carolina 
Institutional Review Board (Pro00090115).77 
Research Questions 
1. What is the influence of insurance-level patient financial liability per visit on 
physical therapy visits and episodic patient reported outcomes in commercially 
and Medicare-insured patients? 
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Data Source and Patient Identification 
The purpose of this investigation was to better understand the influence of 
baseline patient characteristics and health insurance attributes on physical therapy visit 
utilization and PRO change. Commercially-insured patients 18 – 64 years of age that 
received physical therapy for nonoperative LBP at ATI Physical Therapy across 26 states 
in the United States (U.S.) between January 1, 2017 and December 31, 2018 were 
considered for inclusion. Commercially-insured patients were the focus of this study for 2 
primary reasons. First, they were the most prevalent insurance payer observed in the 
database—covering roughly 55% of patients treated for LBP. Second, commercial payers 
provided a representative sample with wide variation in policy options with vastly 
different payment structures that impact patient financial liability. 
Baseline patient demographic information, initial and final Modified Low Back 
Pain Disability Questionnaire (MDQ) outcomes, patient financial liability, and physical 
therapy billing and utilization information for all patients were extracted from the ATI 
Patient Outcomes Registry. Nonoperative LBP was defined for this Research Question as 
LBP with no self-reported surgical intervention related to the lumbar spine within 120 
days of initial physical therapy evaluation. Because recurrence of LBP is common, all 
patient episodes were considered separately. This allowed for a practical and 
representative sample of patients commonly treated in physical therapy settings. While 
ideally recurrence would have been known and used as a control variable, we were 
unable to control for episodes of LBP prior to a patient’s initial start date within ATI 
Physical Therapy—nor could we control for any healthcare services for LBP outside of 
ATI Physical Therapy.  
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Physical Therapy Variables Typically Acquired During Treatment Episode 
Demographic, health history, physical therapy visit count, and PRO data acquired 
during the typical physical therapy episode of care for patients with LBP were extracted 
from the ATI Patient Outcomes Registry, registered with ClinicalTrials.gov 
(NCT02285868) and the U.S. Department of Health and Human Services Agency for 
Healthcare Research and Quality in the Registry of Patient Registries (2608). An episode 
of care was defined as all services rendered from initial physical therapy evaluation 
through final observed MDQ in the electronic health record.  
Available demographic information included age, sex, body mass index (BMI), 
commercial payer attributes (i.e., copayment, deductible and coinsurance), and SES—
using ZIP-level median annual income as a proxy. Baseline disability level was 
determined by the initial MDQ score calculated at the initial physical therapy evaluation. 
Available health history was patient-reported via medical history form in the form of yes-
no response to 31 commonly reported health conditions and symptoms, of which each 
was considered separately as a covariate. The candidate IV, insurance plan-level patient 
financial liability per visit, and number of physical therapy visits from initial to final 
MDQ was queried from episode-level information within the ATI Patient Outcomes 
Registry. Finally, the change from initial to final MDQ was the terminal outcome of 
interest as described below.22,36,78 
Variable Utilization 
Terminal Outcomes of Interest 
The PRO change from initial to final MDQ was considered as the primary 
terminal outcome. Change in MDQ offers a validated measure for whom important 
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change is well-understood and recognized.22,34,36 Further, it was recently validated as a 
performance measure to assess the quality of physical therapy providers.16,30 
First-Stage: Variables Theorized to Influence Treatment Choice (Physical Therapy 
Visits) 
Chapter 1 highlighted all information known or theorized to influence physical 
therapy visit and/or utilization and PRO change. Of those listed, the following were 
available in the ATI Physical Therapy Patient Outcomes Registry and considered for 
inclusion in the first stage regression equation. First, demographic characteristics 
associated with physical therapy and/or healthcare utilization including sex, BMI, and 
age were obtained.79 Second, patients’ ZIP-level median income was used as a proxy for 
socioeconomic status (SES), another patient factor associated with healthcare 
utilization.79 Finally, initial disability related to LBP (i.e., initial MDQ), health status 
(i.e., initial Veteran’s RAND 12-Item Health Survey [VR-12]), status as chronic 
condition, and comorbid conditions were derived as they also have been demonstrated to 
influence physical therapy utilization.16,79 While a validated comorbidity measure such as 
the Charlson Comorbidity Index was not available within the data, inclusion of a patient-
reported comorbid health history functioned as a proxy as it has in prior outcomes 
research.16,30,80 
To address the validity and interpretability concerns of having differing structures 
of insurance attributes (i.e., copayment, deductible and coinsurance), average patient 
financial liability per physical therapy visit averaged across an insurance plan structure 
for a given year was considered as the IV. Patients insured by a health insurance plan 
with fewer than 20 patients were excluded from the final analyses. This insurance-level 
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value was exogenous to any one patient in the sample as it was derived from a broader 
sample of like-insured patients. 
Second Stage: Variables Theorized to Influence Outcomes of Interest (Change/Final 
MDQ) 
All baseline variables (aside from the candidate IV) were included in the Second 
Stage regression equation; the First Stage predicted visit count was also included.16,17,27-
30,34 Demographic characteristics including sex, BMI, and age have been demonstrated to 
influence PRO change.16,17,28,29 ZIP-level median income as a proxy for SES has been 
demonstrated to significantly influence MDQ change.16 Finally, baseline disability per 
initial PRO, baseline health status per VR-12, status as chronic condition, and reported 
comorbid conditions have also been demonstrated to influence PRO and MDQ 
outcomes.16,17,28,29 Table 2.1 describes variable utilization by regression stage for 
Research Question 1. 
Testing Assumptions of the Candidate Instrumental Variable 
While variation in health insurance attributes such as copayment and deductible 
with coinsurance were known or theorized to impact physical therapy utilization 
(Condition 1), there was no direct theoretical link from these health insurance attributes 
to health outcomes in patients with LBP beyond differences that exist due to variation in 
healthcare utilization (Condition 2).51 While the insured may attempt to tailor a plan to 
meet their anticipated musculoskeletal healthcare needs, requiring a 20-patient minimum 
by plan ensured that the IV was exogenous to any 1 patient (Condition 3). Consistent 
with the recommendation of Harris and Remler69 and recent work by Brooks et al65, 
baseline information observable at the time of initial evaluation (i.e., initial MDQ and 
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VR-12, sex, age, BMI, time from onset to initial physical therapy evaluation 
dichotomized as acute or chronic (>90 days), patient ZIP-level median annual income, 
and count of comorbid conditions per patient-reported medical history) were compared 
after dividing included patients into subsets by the instrumental variable (i.e., quintile). 
Finally, it was logically theorized that increasing a patient’s financial burden for 
treatment would have a monotonic relationship with the probability of receiving 
treatment (Condition 4). In other words, increasing patient financial liability per visit was 
only theorized to decrease the likelihood of more physical therapy visits. It was our belief 
that patient financial liability met the 4 conditions and was appropriate for use as an 
instrument. 
Measurement Properties of the Modified Low Back Pain Disability Questionnaire 
(MDQ) 
The MDQ utilizes a 50-point scale that is converted to a percentage with 0% 
indicating absence of disability and 100% indicating complete disability. A minimal 
clinically important difference (MCID) of 6 on a 100-point scale has been reported for 
the MDQ; while its similar predecessor (Oswestry Disability Index) has a reported MCID 
of 10.23,36 Additionally, values for standard error of the measure (SEM), minimal 
detectable change (MDC), and intraclass correlation coefficient (ICC) have been reported 






Analytical Approach: Instrumental Variable Regression using Two-Stage Least 
Squares 
Instrumental Variable estimation using two-stage least squares (2SLS) was used 
to better understand the influence of patient financial liability per visit on physical 
therapy visit utilization and MDQ change as described above. 
First Stage: Estimating Treatment Choice (Physical Therapy Visits) 
The first stage of the 2SLS IV approach was used to estimate physical therapy 
visit count using all first stage covariates described above (abbreviated Xin with each n 
representing 1 of k independent variables) and the IV (abbreviated Zi). A representative 
first stage regression equation follows: 
Pi= α0+ α1(Xi1) + α2(Xi2) + … + αk(Xik) + αt(Zi) + εi 
Where i represents an individual patient and: 
· ‘P’ represents physical therapy visits 
·  ‘Xin’ represents each first stage covariate (for 1 to k included independent 
variables) 
· ‘Zi’ represents the instrumental variable (actual patient financial liability) 
· ‘α0’ represents the intercept 
· ‘αn’ represent the coefficients for each covariate (for 1 to k included 
independent variables) 
· ‘αt’ represents the coefficient for the instrumental variable 





Second Stage: Estimating MDQ Change 
The second stage of the 2SLS IV approach was used to estimate MDQ change 
using all second stage covariates described above (abbreviated Xin with each n 
representing 1 of k independent variables) and predicted visit count from the first stage 
above. Representative second stage regression equations are presented below: 
MDQ Changei = β0+ β1(Xi1) + β2(Xi2) + … + βk(Xik) + βt(Pi-hat) + εi 
Where i represents an individual patient and: 
· ‘Change MDQi’ represents total change from initial to final MDQ score 
·  ‘P-hat’ represents predicted physical therapy visits from the first stage 
regression 
·  ‘Xi’ represents each covariate 
· ‘β 0’ represents the intercept 
· ‘βn’ represent the coefficients for each covariate (for 1 to k included 
independent variables) 
· ‘βt’ represents the coefficient for predicted physical therapy visit count 
·  ‘εi’ represents the error 
Summary: Aim 1 Methods 
While many factors are known to impact PROs, this was the first study to explore 
the interrelationship between patient financial liability per visit, physical therapy visit 
utilization, and PRO change. While it is known that referrals to physical therapy are 
impacted by payer type (e.g., commercial, Medicare, Medicaid, Worker’s Compensation) 
and plan structure (e.g., Preferred Provider Organization, Health Maintenance 
Organization), no study to date has examined the influence of baseline patient 
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characteristics, initial PROs, and patient financial liability on physical therapy visit count 
and PRO change.47,60,81 The above research approach sought to inform these gaps in the 
healthcare outcomes and utilization literature. 
2. What is the influence on missingness and loss to follow-up in physical therapy 
outcomes research? 
Data Source & Patient Identification 
The same data sources and patients from Research Question 1 were used for 
Research Question 2. The following methods sought to thoroughly compare patients 
included in the final analytical cohort to those excluded from the study. The rationale for 
this approach was to establish a level of congruency between cohorts of patients to 
estimate a level of confidence in the generalizability of the outcomes from Research 
Question 1. Figure 3.1 in the Chapter 3 details the flow of inclusion and exclusion from 
which comparative cohorts were derived. 
Comparison of Baseline Patient Characteristics 
Independent samples t-tests compared baseline numeric variables (i.e., age, body 
mass index [BMI], Modified Low Back Pain Disability Questionnaire [MDQ], Mental 
[MCS] and Physical [PCS] Component Scores of the Veteran’s RAND 12-Item Health 
Survey [VR-12], count of comorbid conditions, insurance plan-level patient financial 
liability per visit, and census-derived ZIP-level median income) between the included and 
excluded cohorts with 95% confidence intervals (CIs) reported as appropriate. Chi-square 
analyses tested for differences baseline categorical variables (i.e., sex and condition 




Comparison of Predicted ‘Index’ Values: 
The primary investigation used a 2-stage least squares (2SLS) instrumental 
variable (IV) regression approach including all baseline patient factors described above to 
predict physical therapy visit count in the first stage and change in PRO in the second 
stage. In the primary analyses, these models were run using only complete, included 
patients. This study sought to identify 2 novel “Index” values aggregated from all 
baseline information to establish a predicted physical therapy visit count and predicted 
MDQ change for ALL patients. To do this, the 2 regression models were run 
independently—again using only the included cohort. Because patient financial liability 
per visit with a large missing value within these data, it was removed from the first 
equation predicting visit count to allow for comparison. Coefficients derived from these 2 
regression models were then applied to the excluded patients, when possible, to calculate 
“Index” values for excluded patients. Independent samples t-tests were used to compare 
values of predicted visit count and MDQ change between cohorts; 95% confidence 
intervals were also reported to provide clinical context. 
Conclusion 
These investigations sought to bolster the available body of physical therapy 
comparative-effectiveness literature related to patients LBP. Methodology for Research 
Question 1 allowed for a deeper understanding of the influence of patient financial 
liability on physical therapy visit count and PRO change for patients with nonoperative 
LBP; while methodology for Research Question 2 provided evidence for the 
generalizability of results derived from the primary investigation. Collectively, methods 
for Research Questions 1 and 2 provided a framework for which investigators can better 
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understand the relationship between patient characteristics, insurance attributes, clinical 
and financial outcomes, and guideline adherent care in patients with nonoperative LBP. 
 
Table 2.1: Variable Consideration by Instrumental Regression Stage 
for Research Question 1 
 










Veteran’s RAND 12-Item 





Financial Liability Per Visit 
X  
First Stage Regression Outcome: 





Instrumental Variable Regression Analysis
Introduction 
Low back pain (LBP) is the most common orthopedic complaint in the United 
States (U.S.) with an estimated lifetime prevalence of 80%.1 Evidence-based guideline 
care recommendations were introduced to reduce costly and unwarranted variation in the 
evaluation and management of patients seeking medical care for LBP.2,3 Many of these 
care recommendations are routinely applied in outpatient physical therapy settings. 
However, there are mixed results when examining health outcomes following physical 
therapy interventions.5-15 Variable physical therapist performance and heterogeneity of 
treatment effect related to patients’ attitudes, beliefs, willingness to pay and/or 
participate, and predisposition to respond to care likely contribute to these findings.16-19 
Another factor thought to contribute to variable clinical outcomes is physical 
therapy visit count. While sometimes predicated on insurance approval or caps, visit 
count is often influenced by the patient’s ability to pay for additional treatment.82 Recent 
literature and polling provides evidence that healthcare utilization is adversely affected 
by health insurance plans that pass along greater financial responsibility to the patient; 
however, there is no evidence that suggests additional physical therapy utilization will 
grant patients greater improvement in function (i.e., greater PRO change).82-84 The 
purpose of this study was to utilize instrumental variable (IV) regression to exploit 
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natural variation in a physical therapy clinical outcomes database to test this 
relationship.65-67 
IV regression uses a two-stage least squares (2SLS) approach in which the first 
stage regresses all explanatory variables (i.e., baseline demographic and outcome 
information) and candidate IV(s) (i.e., insurance-level patient financial liability per visit) 
to estimate treatment choice (i.e., physical therapy visit count), and the second stage 
simultaneously regresses those same baseline explanatory variables (i.e., demographic 
and outcome information) AND the first stage outcome (i.e., predicted visit count) to 
estimate the terminal health outcome (i.e., PRO change).66,67,85 Results are then 
generalizable to a “marginal” subset of patients whose treatment choice (i.e., number of 
physical therapy visits attended) is influenced by the instrument(s) (i.e., patient financial 
liability per visit).66 IV regression assumes that the IV influences treatment choice but 
has no impact on the outcome of treatment.67,68 Harris and Remler69 highlighted 4 
conditions a variable must meet for consideration as a valid instrument. The candidate 
IV(s) must: 1) influence probability of treatment, 2) not independently effect change in 
the outcome of interest, 3) not be influenced by health status or health outcomes 
(exogeneity), and 4) only influence the probability of treatment in one direction 
(monotonicity). Patient financial liability per visit averaged across a health insurance plan 
was proposed as the IV for this investigation. It was thought to influence the number of 
visits attended; however, there was no direct theorized influence of insurance plan-level 
patient financial liability per visit on PRO change—aside from its effect via visit count. 
Finally, because it was aggregated to the insurance level mean, the IV was exogenous to 
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any 1 patient. Figure 1 details the representative theoretical model regarding the 
hypothesized effect of patient financial liability per visit on physical therapy visits. 
The PRO selected for this study was the Modified Low Back Pain Disability 
Questionnaire (MDQ), a modification of the Oswestry Disability Index (ODI) and the 
most commonly used PRO among physical therapists for patients with LBP.22,32,36 We 
hypothesized that patient financial liability per visit would be a strong instrument that 
would differentiate utilization among marginal patients whose visits were influenced by 
financial concerns. Further, we hypothesized that the additional visits attended by these 
marginal patients would result in additional meaningful change in the MDQ. 
Methods 
Data Sources and Patient Identification: 
Patients with LBP that sought physical therapy care between January 2017 and 
December 2018 were identified from the ATI Patient Outcomes Registry. This registry, 
which is registered with ClinicalTrials.gov (NCT02285868) and the US Department of 
Health and Human Services Agency for Healthcare Research and Quality in the Registry 
of Patient Registries (2608), was also queried for baseline patient information and patient 
reported outcomes (PROs) throughout the physical therapy episode of care. Separate data 
sets also provided granular scheduling data and final adjudicated financial claims for 
identified patients. This study followed the REporting of studies Conducted using 
Observational Routinely collected Data (RECORD) initiative and was reviewed and 





Inclusion & Exclusion Criteria (Figure 3.2): 
An initial query for all nonoperative patients 18-64 years of age with LBP that 
completed the MDQ and Veterans RAND 12-Item Health Survey (VR-12) at an initial 
physical therapy evaluation with commercial insurance yielded 65,924 unique patient 
episodes.43 Only patients with a follow-up MDQ, complete baseline demographic 
information described below, scheduling information, and final adjudicated financial 
claims were included, yielding 25,382 unique patient episodes. Race was missing in 
97.6% of patient episodes and excluded for consideration as a factor. Body mass index 
(BMI) was available for 81.5% of patient episodes and included in models below as 
quintiles. A 6th classification assigned to those with missing BMI to avoid a further 
decline in sample size. Table 3.1 describes the available sample, the cohort of included 
patients, and patients split into quintiles by the instrumental variable (i.e., insurance plan-
level patient financial liability per visit). Chapter 4 further explores the comparison of 
included and excluded patients for an expanded look at generalizability of the below 
clinical findings. 
Statistical Framework & Computing:  
Two-stage least squares (2SLS) instrumental variable (IV) regression with Robust 
Standard Errors (RSEs) was utilized. Detailed above, 2SLS IV regression allows for 
causal inference by exploiting natural variation in the data. Analyses and plots were 






Instrument Development:  
To ensure the proposed IV met the exogeneity requirement—and due to variety of 
health insurance plan structures vary (i.e., copayment or deductible and coinsurance)—
preliminary work was required to develop a suitable instrument. Patients were grouped 
by insurance plan and a mean value of patient financial responsibility per visit between 
initial and final MDQ was calculated and assigned to each patient within the plan. For 
this measure to be exogenous to any 1 patient, a minimum of 20 patients per plan was 
required. This requirement further reduced the final analytical sample to 21,541 unique 
patient episodes. 
Stage 1: Modeling Visit Count 
Stage 1 included patient financial liability per visit as the IV and modeled the 
number of physical therapy visits attended by each patient. Additional explanatory 
variables theorized to influence physical therapy visits included patient sex, payer (i.e., 
Medicare or Commercial), quintile of age at initial evaluation, quintile of BMI at initial 
evaluation (with a 6th category for the 18.5% with missing BMI), stage of physical 
therapy services, ZIP-level median income where the patient resides, initial MDQ, initial 
mental (MCS) and physical (PCS) component scores of the Veteran’s RAND 12-Item 
Health Survey (VR-12), and individual comorbidities identified from a patient-reported 
medical history form. 
Stage 2: Modeling MDQ Change 
The Stage 1 predicted physical therapy visit count was included in the Stage 2 
regression predicting MDQ change. Explanatory variables used in Stage 1 have been 
demonstrated to influence PRO change and were also included in Stage 2.16,17,27,28 
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Because these variables were used in Stage 1 to predict visit count, only the portion of 
these independent variables that predict change in MDQ independent of their indirect 
effect on change in MDQ through predicted number of physical therapy visits attended 
was accounted for in this stage. 
Results 
Inclusion and exclusion criteria were met for 21,541 unique patient episodes 
(Table 3.1). Insurance-level mean patient financial liability was $42 per visit (range $8, 
$142). The first-stage F-test indicated borderline strength of the IV (F = 9.8); however, 
the effect of the IV trended opposite to theoretical model by quintile of the IV (Table 
3.2). Visit count predicted in the first stage was a statistically significant positive 
predictor of MDQ change (P = 0.02) with a 0.8 point increase in MDQ change per 
additional “marginal” visit. 
Table 3.1 describes patients by quintile of patient financial liability per visit. 
Baseline values by quintile were relatively uniform aside from ZIP-level median income, 
which was observed to be lower in quintile 3. There were no other clinically important 
differences identified between quintiles. Tables 3.2 and 3.3 highlight first and second 
stage regression coefficients, respectively, with robust standard errors and 95% CIs 
provided. Select comorbid history, initial MDQ, ZIP-level median income, chronic status, 
patient financial liability exceeding $45 per visit, age exceeding 52.5 years, and initial 
VR-12 PCS were the strongest predictors of physical therapy visit count; while select 
comorbid history, sex, initial MDQ, initial VR-12 MCS and PCS, chronic status, body 
mass index (BMI) exceeding 33.1, and predicted visits were the strongest predictors of 




Summary of Findings: 
Patient financial liability did not function in a manner consistent with a priori 
theory. The IV demonstrated borderline strength per the first stage F-test; however, as 
patient financial liability per visit increased, visits trended upward. This is a major 
limitation to the study as the underlying theoretical framework was proven false; further 
detailed below. Consistent with prior investigations, initial PRO and VR-12, chronic 
status, status of services, sex, and select comorbidities were significant predictors of PRO 
change.16,17,27,28 Interestingly, while ZIP-level median income was previously identified 
as a significant predictor of MDQ change, it was not a significant predictor in the 2nd 
stage regression equation. Instead, it significantly influenced physical therapy visit count, 
and previously identified effect on MDQ change may have been indirect through its 
effect on visit count. 
Instrumental Variable Utility: 
A retrospective analysis of insurance plan-level patient financial liability per visit 
as an instrument identifies significant weaknesses in its use.69 While patient financial 
liability per physical therapy visit demonstrated borderline strength as an instrument, the 
generally monotonic relationship the IV had with visit count trended away from the 
theorized direction. As a result, no significant inferences can be derived from the data as-
is. It is believed this was a function of missing individual-level socioeconomic status and 
plan structure. Recent evidence supports the idea that these unmeasured confounders—
specifically high income beneficiaries selecting high deductible, health savings account-
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style policies and trending toward increased healthcare use despite greater patient 
financial liability—likely contribute to these results.47,70 
Interpretation of Findings:  
While a natural experiment was observed in Table 3.1, findings were likely 
influenced more by individual socioeconomic status and insurance plan structure than 
previously hypothesized. A telling finding in support of this hypothesis is the dip in visit 
count in the 3rd quintile—consistent with the dip in ZIP-level median income. An ideal 
methodological framework would allow for control of area SES (ZIP-level), individual-
level SES, plan structure (i.e., copayment-based, low deductible coinsurance-based, and 
high deductible coinsurance-based), and the interaction of individual-level SES and plan 
structure. While it is unlikely that individual-level SES will ever become available in a 
real-world electronic health record-based study, further investigation including plan 
structure is warranted. 
Aside from concerns regarding the IV, the coefficient for visit count was 0.8 
(95% CI 0.1,1.5). Since this applies only to “marginal” visits, this additional change is 
not one that approaches clinical significance. With values of MCID estimated at 6 and 10, 
these results indicate that a minimum of 6-7 additional visits would be required before 
clinical change would occur. 
Limitations:  
Secondarily obtained observational data are not obtained for research purposes, 
and therefore are subject to unmeasured confounding. A prior study highlighted that only 
19% of variability in change in MDQ is associated with measured baseline patient 
characteristics leaving the vast majority of variance unexplained.16 Secondly, the IV did 
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not function as hypothesized. As described above, issues with the IV likely arose due to 
lacking information related to individual SES and health insurance plan structure. Due to 
this limitation, more detailed baseline information is required before confidence in the 
results of these analyses is established. Finally, Chapter 4 explores the generalizability of 
physical therapy patient reported outcomes research as a result of those lost to follow-up. 
In addition to the 42.6% of patients that failed to complete a follow-up MDQ, an 
additional 14.8% of the total population had scheduling, ZIP-level median income, or 
financial liability information missing—or were enrolled in a health insurance plan with 
fewer than 20 enrollees in our data sample. This leaves a final sample of 21,541 (32.7%) 
from which inferences were made. While this remains a large sample—there were more 
patients excluded (n = 65,924 [67.3%]) than included and this limits the generalizability 
of our results. 
Conclusions 
Patient financial liability per visit influenced visit count in a marginal population 
of patients—but the associated difference was counter to a priori hypotheses. Additional 
data is warranted to test the theory that plan structure plans a large role in the proposed 
interrelationship between patient financial liability, visit count, and PRO change. While 
an ideal model would include individual-level SES, this is unmeasurable in a secondarily 





Table 3.1: Description of Total Patients, Included Sample, and Quintiles of Patient Financial Liability Per Visit 
 






Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
Count 65,924 21,541 4,752 3,840 4,459 4,337 4,153 
Age 46.4 ± 12.7 46.2 ± 12.9 47.0 ± 13.1 45.7 ± 12.9 46.3 ± 13.1 46.6 ± 12.5 45.1 ± 12.7 

































Initial MDQ 32.2 ± 17.7 31.3 ± 15.4 32.3 ± 17.8 30.7 ± 17.1 31.5 ± 16.6 31.3 ± 16.7 30.7 ± 17.0 
MDQ Changeǂ 10.6 ± 15.2 11.3 ± 15.4 10.3 ± 15.4 11.6 ± 15.5 11.3 ± 15.3 11.7 ± 15.2 11.6 ± 15.6 
Initial  
VR-12 MCS 
39.2 ± 6.9 39.3 ± 6.9 39.3 ± 6.9 39.7 ± 6.6 39.3 ± 6.7 39.3 ± 6.8 39.8 ± 6.6 
Initial 
VR-12 PCS 
37.6 ± 6.3 37.6 ± 6.2 37.3 ± 6.2 37.7 ± 6.3 37.5 ± 6.1 37.6 ± 6.1 37.8 ± 6.3 
Comorbidity 
Count 
2.3 ± 2.5 2.2 ± 2.3 2.4 ± 2.5 2.0 ± 2.1 2.3 ± 2.3 2.2 ± 2.2 2.0 ± 2.1 

















Values Represent Mean ± Standard Deviation or Count (Column %) 







Table 3.2: First Stage Instrumental Variable Regression Coefficients Predicting Physical 










Intercept 9.1 -3.2,21.5 6.2 1.476 0.140 
Initial MDQ 0.04 0.03,0.04 0.00 13.658 <0.001*** 
Initial VR12 – MCS -0.01 -0.02,0.01 0.01 -1.129 0.259 
Initial VR12 – PCS -0.03 -0.04,-0.01 0.01 -3.722 <0.001*** 
BMI: Quintile 2 0.0 -0.3,0.3 0.1 0.057 0.955 
BMI: Quintile 3 -0.1 -0.4,0.2 0.2 -0.720 0.471 
BMI: Quintile 4 -0.1 -0.4,0.2 0.2 -0.481 0.631 
BMI: Quintile 5 0.3 0.0,0.6 0.2 2.106 0.035* 
BMI: Missing -0.1 -0.4,0.2 0.1 -0.559 0.576 
Age: Quintile 2 -0.4 -0.7,-0.1 0.1 -3.046 0.002** 
Age: Quintile 3 -0.5 -0.8,-0.2 0.1 -3.415 0.001** 
Age: Quintile 4 -0.6 -0.9,-0.3 0.1 -4.193 <0.001*** 
Age: Quintile 5 -0.6 -0.9,-0.3 0.2 -3.682 <0.001*** 
Condition ≥ 90 Days 0.5 0.3,0.8 0.1 4.161 <0.001*** 
Sex (Male) -0.3 -0.5,-0.1 0.1 -2.959 0.003** 
History: 
Bowel & Bladder 
Problems 
0.2 -0.1,0.6 0.2 1.511 0.131 
History: 
High Blood Pressure 
0.1 -0.1,0.3 0.1 0.693 0.488 
History: 
Diabetes (Any) 
0.2 -0.1,0.5 0.2 1.199 0.230 
History: 
Allergy (Non-Latex) 
0.5 0.3,0.7 0.1 4.869 <0.001*** 
History: 
Smoking 
-0.5 -0.7,-0.2 0.1 -3.589 <0.001*** 
History: 
Night Sweats &/or Pain 
0.2 -0.1,0.4 0.1 1.229 0.219 
History: 
Cancer 
0.2 -0.2,0.6 0.2 0.944 0.345 
History: 
Metal Implants 
0.4 0.1,0.8 0.2 2.942 0.003** 
History: 
Groin Numbness 
-0.1 -0.6,0.4 0.3 -0.385 0.700 
History: 
Fracture 
0.3 -0.1,0.6 0.2 1.355 0.175 
History: 
Arthritis (Any) 
0.0 -0.2,0.2 0.1 0.217 0.828 
History: 
Stroke 
0.0 -0.8,0.8 0.4 0.038 0.970 
History: 
Allergy – Latex 
0.0 -0.4,0.5 0.2 0.182 0.855 
History: 
Ringing in Ears 







-0.3 -1.0,0.3 0.3 -1.013 0.311 
History: 
Heart Condition 
-0.3 -0.7,0.1 0.2 -1.532 0.126 
History: 
Blood Clot / 
Deep Vein Thrombosis 
0.8 0.3,1.4 0.3 2.901 0.004** 
History: 
Kidney Condition 
-0.6 -1.1,0 0.3 -2.180 0.029* 
History: 
Sexual Dysfunction 
0.4 -0.1,0.9 0.2 1.479 0.139 
History: 
Seizures 
0.4 -0.3,1.2 0.4 1.128 0.259 
History: 
Pregnant 
-0.8 -1.5,-0.1 0.4 -2.248 0.025* 
History: 
Fever or Nausea 
0.0 -0.5,0.6 0.3 0.149 0.882 
History: 
Double Vision 
-0.8 -1.5,-0.1 0.3 -2.337 0.019* 
History: 
Unexplained Weight Loss 
0.1 -0.8,1 0.5 0.204 0.838 
History: 
Pacemaker 
0.5 -0.7,1.7 0.6 0.886 0.375 
History: 
Breathing Difficulties / 
Asthma 
0.2 -0.1,0.4 0.1 1.335 0.182 
History: 
Difficulty Swallowing 
0.3 -0.3,0.9 0.3 1.024 0.306 
History: 
Osteoporosis 
-0.5 -0.9,-0.1 0.2 -2.324 0.020* 
History: 
Psychological Condition 
0.5 0.1,0.8 0.2 2.681 0.007** 
History: 
Chest Pain 
0.3 -0.2,0.7 0.2 1.113 0.266 
ZIP-Level Median Income 
(per $10,000) 
0.1 0.1,0.1 0.0 5.711 <0.001*** 
Financial Liability Per 
Visit: Quintile 2 
0.2 -0.1,0.5 0.1 1.655 0.098 
Financial Liability Per 
Visit: Quintile 3 
-0.1 -0.5,0.2 0.2 -0.797 0.425 
Financial Liability Per 
Visit: Quintile 4 
0.7 0.4,1.0 0.2 4.240 <0.001*** 
Financial Liability Per 
Visit: Quintile 5 
0.6 0.3,1.0 0.2 3.514 <0.001*** 
Coefficients, Confidence Intervals (CIs), and Errors Rounded to 1 Decimal Except as Noted 

















Intercept -22.5 -29.9,-15.2 3.7 -6.113 <0.001*** 
Initial MDQ 0.49 0.46,0.52 0.02 31.285 <0.001*** 
Initial VR12 – MCS 0.16 0.13,0.20 0.02 9.220 <0.001*** 
Initial VR12 – PCS 0.15 0.11,0.19 0.02 7.024 <0.001*** 
BMI: Quintile 2 0.1 -0.6,0.7 0.3 0.181 0.856 
BMI: Quintile 3 0.1 -0.6,0.8 0.3 0.326 0.745 
BMI: Quintile 4 0.4 -0.3,1.1 0.3 1.146 0.252 
BMI: Quintile 5 -1.7 -2.4,-0.9 0.4 -4.399 <0.001*** 
BMI: Missing -0.6 -1.3,-0.0 0.3 -2.006 0.045* 
Age: Quintile 2 -0.5 -1.2,0.1 0.3 -1.654 0.098 
Age: Quintile 3 -1.1 -1.8,-0.4 0.4 -3.270 <0.001*** 
Age: Quintile 4 -1.3 -2.0,-0.5 0.4 -3.347 0.001** 
Age: Quintile 5 -1.5 -2.2,-0.7 0.4 -3.727 <0.001*** 
Condition ≥ 90 Days -2.1 -2.8,-1.5 0.3 -6.618 <0.001*** 
Sex (Male) 1.3 0.9,1.8 0.2 5.784 <0.001*** 
History: 
Bowel & Bladder 
Problems 
-2.1 -2.8,-1.3 0.4 -5.461 <0.001*** 
History: 
High Blood Pressure 
-0.5 -1.0,0.0 0.3 -1.918 0.055 
History: 
Diabetes (Any) 
-1.3 -2.0,-0.5 0.4 -3.308 0.001** 
History: 
Allergy (Non-Latex) 
-0.2 -0.8,0.4 0.3 -0.517 0.605 
History: 
Smoking 
-1.3 -2.0,-0.6 0.4 -3.617 <0.001*** 
History: 
Night Sweats &/or Pain 
-2.9 -3.5,-2.3 0.3 -9.712 <0.001*** 
History: 
Cancer 
0.5 -0.5,1.4 0.5 1.032 0.302 
History: 
Metal Implants 
-2.7 -3.5,-1.9 0.4 -6.788 <0.001*** 
History: 
Groin Numbness 
-2.4 -3.6,-1.2 0.6 -4.021 <0.001*** 
History: 
Fracture 
-0.8 -1.7,0.0 0.4 -1.934 0.053 
History: 
Arthritis (Any) 
-2.8 -3.3,-2.3 0.2 -11.278 <0.001*** 
History: 
Stroke 
-2.1 -4.1,-0.0 1.0 -1.978 0.048* 
History: 
Allergy – Latex 
-1.1 -2.2,-0.1 0.5 -2.125 0.034* 
History: 
Ringing in Ears 







0.0 -1.5,1.5 0.8 0.033 0.973 
History: 
Heart Condition 
-0.1 -1.0,0.8 0.4 -0.280 0.780 
History: 
Blood Clot / 
Deep Vein Thrombosis 
0.4 -1.1,1.8 0.7 0.523 0.601 
History: 
Kidney Condition 
0.1 -1.1,1.4 0.6 0.232 0.817 
History: 
Sexual Dysfunction 
-2.4 -3.6,-1.2 0.6 -3.993 <0.001*** 
History: 
Seizures 
-3.6 -5.6,-1.7 1.0 -3.754 <0.001*** 
History: 
Pregnant 
-4.7 -6.8,-2.7 1.0 -4.712 <0.001*** 
History: 
Fever or Nausea 
-0.3 -1.6,1.0 0.6 -0.430 0.667 
History: 
Double Vision 
-0.8 -2.6,1.0 0.9 -0.868 0.385 
History: 
Breathing Difficulties / 
Asthma 
-0.9 -4.3,-0.0 1.1 -1.967 0.049* 
History: 
Unexplained Weight Loss 
-2.2 -3.3,1.6 1.2 -0.732 0.464 
History: 
Pacemaker 
-0.9 -1.5,-0.3 0.3 -2.817 0.005** 
History: 
Difficulty Swallowing 
-0.9 -4.3,-1.4 0.7 -3.979 <0.001*** 
History: 
Osteoporosis 
-2.9 -1.0,1.2 0.5 0.189 0.850 
History: 
Psychological Condition 
0.1 -3.0,-1.2 0.5 -4.584 <0.001*** 
History: 
Chest Pain 
-2.1 -2.7,-0.5 0.6 -2.799 0.005** 
ZIP-Level Median Income 
(per $10,000) 
.00 -0.12,0.12 0.06 0.122 0.903 
Predicted Physical 
Therapy Visit Count 
0.8 0.1,1.5 0.4 2.329 0.020* 
Coefficients, Confidence Intervals (CIs), and Errors Rounded to 1 Decimal Except as Noted 























Generalizability of Comparative Effectiveness Research with Missing Data
Introduction 
Research endeavors often take place in a ‘real world’ environment to improve 
available sample and maximize generalizability.16,17,27-29,52,72,73 The United States 
Department of Health and Human Services defines comparative effectiveness research 
(CER) as research that compares “the benefits and harms of different interventions and 
strategies to prevent, diagnose, treat and monitor health conditions in “real world” 
settings.”74 It aims to clarify the effectiveness of established health interventions.75 
Donabedian61 called health outcomes the “ultimate validators of the effectiveness and 
quality of medical care”. Health outcomes, including PROs, are often missing in these 
‘real world’ research designs, leading investigators to explain away the missingness and 
its effect on validity and generalizability.62-64 While problematic in prospective cohort-
based studies, the problem of missing PROs is magnified when examining secondarily 
obtained observational data from electronic health records (EHRs) and other healthcare 
databases. Patient reported outcomes derived from EHRs are often used in orthopaedic 
physical therapy research to test the effectiveness of interventions and 
therapists.9,16,17,24,25,27-30,33,34 There is wide variation in collection of follow-up PROs 
across the rehabilitation industry, and little is understood regarding the appropriate 





Because “real world” health information—and pragmatic research approaches—
often lack data, it would be beneficial to better understand how generalizable the 
inferences made on the “complete cases” is to the broader, less complete patient 
population. As a representative sample, the initial cohort of patients with LBP identified 
in Chapter 3 required the inclusion of several distinct data sets, limiting the included 
sample to 32.7% of the available patients with low back pain (LBP). The purpose of this 
study was to thoroughly vet baseline patient information and patient reported outcomes 
(PROs) to establish a level of confidence of generalizability of the results to the broader 
physical therapy patient population. While baseline patient information accounts for less 
than 40% of the variability in change of PROs, if these data are comparable between 
included and excluded cohorts, it would improve confidence in the generalizability of our 
results and inferences.16,17,30 We hypothesized that these baseline values would be 
comparable, and the inferences made would generalize well to the broader patient 
population—understanding that limitations remain, given the unexplained variability. 
Methods 
Data Sources: 
Commercially insured, nonoperative patients 18 to 64 years of age with LBP that 
sought physical therapy care between January 2017 and December 2018 were identified 
from the ATI Patient Outcomes Registry. This registry, which is registered with 
ClinicalTrials.gov (NCT02285868) and the US Department of Health and Human 
Services Agency for Healthcare Research and Quality in the Registry of Patient 
Registries (2608), was also queried for baseline patient information and patient reported 




provided scheduling information and final adjudicated financial claims data for identified 
patients. This study followed the REporting of studies Conducted using Observational 
Routinely collected Data (RECORD) initiative and was reviewed and approved by The 
University of South Carolina Institutional Review Board (Pro00090115).77 
Inclusion & Exclusion Criteria: 
Chapter 3 (Figure 3.2) details the process from which the final included 
(n=21,541) and excluded (n=44,383) samples were derived. 
Comparison of Baseline Patient Characteristics: 
Independent samples t-tests compared baseline numeric variables (i.e., age, body 
mass index [BMI], Modified Low Back Pain Disability Questionnaire [MDQ], Mental 
[MCS] and Physical [PCS] Component Scores of the Veteran’s RAND 12-Item Health 
Survey [VR-12], count of comorbid conditions, insurance plan-level patient financial 
liability per visit, and census-derived ZIP-level median income) between the included and 
excluded cohorts with 95% confidence intervals (CIs) reported; while chi-square analyses 
tested for differences baseline categorical variables (i.e., sex and condition present ≥ 90 
days at initial evaluation). 
Comparison of Predicted ‘Index’ Values: 
The investigation in Chapter 3 involved a 2-stage least squares (2SLS) 
instrumental variable (IV) regression approach using all baseline patient factors described 
above (i.e., age, BMI, initial MDQ, initial VR-12 mental and physical component scores, 
individual comorbid conditions, chronic status, ZIP-level median income, and the IV—
insurance-level patient financial liability per visit) to predict visit count in the first 




level patient financial liability per visit) to predict PRO change in the second stage. The 
first stage model—excluding insurance-level patient financial liability per visit—was 
then run separately using the included cohort of patients. Coefficients derived from this 
model were then applied to excluded patients for whom all baseline information was 
available for calculation of a single comparator “index” value for predicted visits. 
Similarly, the second stage model—excluding predicted visit count—was run separately 
using the included cohort of patients. Coefficients from this model were also derived and 
applied to excluded patients with all available baseline information for calculation of a 
single comparator “index” value for predicted MDQ change. Independent samples t-tests 
were used to compare values of predicted visit count and change in MDQ between 
cohorts, and 95% confidence intervals were reported for additional clinical context. 
Statistical Computing: 
Analyses and plots were completed in R, with plots requiring the ‘ggplot2’ 
package.76,87 
Results 
Baseline and Clinical Course of Care Comparisons 
Baseline comparisons were made between the 21,541 unique included patient 
episodes and 44,383 unique excluded patient episodes, as available. Table 4.1 describes 
patients in each cohort, including the number of missing values by variable in the 
excluded group. Table 4.1 also compares these values for statistical significance. Of the 
observed baseline clinical factors, age, sex, initial MDQ, comorbidity count, and 




between cohorts (P<0.001). Of the clinical course of care factors, attended visits and 
MDQ change were also statistically different between cohorts (P<0.001).  
Index Comparisons 
Of the 44,383 excluded patient episodes, the vast majority (n = 41,354) had 
required baseline information described above as required for regression modeling 
predicting “index” values of predicted physical therapy visit count and MDQ change. 
Tables 4.2 and 4.3 detail coefficients with robust standard errors and statistical 
significance derived for predicted visit count and MDQ, respectively. The “index” value 
for predicted visit count was statistically different (P<0.001) between all included 
patients (13.1 ± 1.7) and all excluded patients (12.9 ± 1.8). The “index” value for 
predicted MDQ change was also statistically different (P<0.001) between all included 
patients (11.3 ± 8.3) and all excluded patients (10.9 ± 8.6). Histograms represented in 
Figures 4.1 and 4.2 compare predicted visit count and MDQ change between cohorts, 
respectively. 
Discussion 
The above results were further analyzed to determine if differences reached the 
level of clinical importance. While statistical differences were identified for initial MDQ 
(1.4 points on a 100 point scale), insurance-level patient financial responsibility per visit 
($2.80 per visit), VR-12 MCS (0.5), comorbidity count (historical difference of 0.2 
comorbidities), and sex (1.1% difference), these differences do not appear to represent 
clinically important amounts.22,36 Differences in visits attended between the included and 
excluded cohorts (6.0 visits) were statistically different—and appear to also represent 
clinical importance. While this difference appears large, it is a logical disparity—as 




reason for undertaking this in-depth analysis. Possibly related to the lower visit count—
and discussed extensively in Chapter 3—is the significantly lower ZIP-level median 
income in the excluded patients ($3,520 lower annually). It is possible, but impossible to 
verify, that many of these patients were unable to complete care as recommended due to 
financial barriers to care. Finally, MDQ change (1.9 points on a 100 point scale) was 
statistically different between cohorts; however, minimal clinically important differences 
of 6 and 10 have been published for the Oswestry Disability Index and its modified 
versions, making the observed difference clinically unimportant.22,36 
The ‘index’ measures of predicted visit count and change in MDQ failed to 
identify clinically important differences. While baseline information explains only 6.1% 
of variability in predicted visit change and 28.5% of variability in change in MDQ, this 
study confirms that independent baseline values and the aggregated ‘index’ scores for 
predicted visit count and change in MDQ are largely the same between cohorts of 
included and excluded patients. 
Management of missing data is of broad interest in outcomes research. 
Investigators are often forced to explain away the importance of missing data (as we have 
here) and/or use complex methods to account for the absence of importance information. 
Mean imputation and inverse probability weighting have been used in orthopaedic 
physical therapy outcomes research; however, those methods simply offer educated 
guesses at the outcome(s) or differently weight the included patients relative to their 
likelihood of outcome completion, respectively, and limitations persist in their 




between included and excluded patients, our confidence in generalizability will continue 
to improve and we can become less reliant on these complex statistics. 
Conclusions 
Few clinically important differences in baseline patient and clinical course of care 
information was identified between included and excluded cohorts, as noted above. 
While results of this study provide evidence of generalizability of results of findings in 
Chapter 3—and broadly to other pragmatic physical therapy outcomes studies—there 
remains some caution when considering generalizability of results. Large amounts of 
unexplained variance in models predicting visit count and change in MDQ remain. 
Factors known or theorized to influence these outcomes such as patient financial liability 
per visit, individual-level socioeconomic status, individual health insurance plan 
structure, provider, clinic, and race could not be accounted for in the above regression 
models due to missing or unknown information (i.e., race and patient financial liability 
across the vast majority of the excluded cohort) or incongruence with the methods in 
Chapter 3 (i.e., provider and clinic) as they resulted in singularity of the two-stage least 
squares regression model utilized.16,17,25,27-30 Even so, using all available information, we 
were unable to identify differences between the included and excluded cohorts that would 


















Total Count n = 21,541 n = 44,383  
Visits 13.1 ± 7.1 0 7.1 ± 6.1 0 P < 0.001* 
Initial MDQ¹ 31.3 ± 17.1 0 32.7 ± 18.0 0 P < 0 .001 
MDQ¹ Change 11.3 ± 15.4 0 9.4 ± 14.9 
31,313 
(70.6%) 





42.3 ± 17.5 0 39.5 ± 17.5 
13,327 
(30.0%) 









91 (0.2%) P < 0.001* 
BMI² 29.2 ± 6.9 
4,022 
(18.7%) 
29.5 ± 7.0 
9,068 
(20.4%) 
P < 0.001 
Age 46.2 ± 12.9 0 46.4 ± 12.6 0 P = 0.012 
Comorbidity 
Count 
3.3 ± 2.8 0 3.0 ± 2.8 0 P < 0.001 
VR12³ MCS⁴ 39.5 ± 6.7 0 39.1 ± 7.0 2,943 (6.6%) P < 0.001 







0 P = 0.008 
Values Represented as Mean ± Standard Deviation or Count (%) 
¹ Modified Low Back Pain Disability Questionnaire,  
² Body Mass Index, ³ Veterans RAND 12-Item Health Survey,  






Table 4.2: Regression Coefficients Predicting Physical Therapy Visit Count: Derived 
from Included Patient Cohort (Note: Coefficients for State of Physical Therapy 







Intercept 70 6.7 1.051 0.293 
Initial MDQ 0.05 0.00 15.661 <0.001*** 
Initial VR12 – MCS 0.00 0.01 -0.562 0.574 
Initial VR12 – PCS -0.03 0.01 -3.063 0.002** 
BMI: Quintile 2 0.0 0.2 -0.283 0.777 
BMI: Quintile 3 -0.2 0.2 -0.936 0.349 
BMI: Quintile 4 -0.2 0.2 -1.010 0.313 
BMI: Quintile 5 0.3 0.2 1.810 0.07 
BMI: Missing -0.1 0.2 -0.471 0.638 
Age: Quintile 2 -0.3 0.1 -1.962 0.05 
Age: Quintile 3 -0.4 0.2 -2.734 0.006** 
Age: Quintile 4 -0.6 0.2 -4.011 <0.001*** 
Age: Quintile 5 -0.7 0.2 -4.056 <0.001** 
Condition ≥ 90 Days 0.4 0.1 2.934 0.003** 
Sex (Male) -0.3 0.1 -3.367 0.001** 
History: 
Bowel & Bladder Problems 
0.3 0.2 1.752 0.080 
History: 
High Blood Pressure 
0.1 0.1 0.968 0.333 
History: 
Diabetes (Any) 
0.2 0.2 1.235 0.217 
History: 
Allergy (Non-Latex) 
0.5 0.1 4.629 <0.001*** 
History: 
Smoking 
-0.5 0.1 -3.499 <0.001*** 
History: 
Night Sweats &/or Pain 
0.2 0.1 1.546 0.122 
History: 
Cancer 
0.2 0.2 0.732 0.464 
History: 
Metal Implants 
0.6 0.2 3.386 0.001** 
History: 
Groin Numbness 
-0.3 0.3 -0.940 0.347 
History: 
Fracture 
0.7 0.2 3.336 0.001** 
History: 
Arthritis (Any) 
0.1 0.1 0.872 0.383 
History: 
Stroke 
-0.1 0.4 -0.288 0.773 
History: 
Allergy – Latex 
0.0 0.2 -0.128 0.898 
History: 
Ringing in Ears 
0.3 0.2 2.035 0.042* 
History: 
Infection 






-0.3 0.2 -1.687 0.092 
History: 
Blood Clot / 
Deep Vein Thrombosis 
0.9 0.3 2.998 0.003** 
History: 
Kidney Condition 
-0.7 0.3 -2.397 0.017* 
History: 
Sexual Dysfunction 
0.5 0.3 2.053 0.040* 
History: 
Seizures 
0.5 0.4 1.335 0.182 
History: 
Pregnant 
-0.9 0.4 -2.422 0.015* 
History: 
Fever or Nausea 
0.1 0.3 0.331 0.741 
History: 
Double Vision 
-0.6 0.4 -1.722 0.085 
History: 
Unexplained Weight Loss 
0.6 0.5 1.155 0.248 
History: 
Pacemaker 
0.4 0.6 0.639 0.523 
History: 
Breathing Difficulties / 
Asthma 
0.2 0.1 1.081 0.280 
History: 
Difficulty Swallowing 
0.3 0.3 0.972 0.331 
History: 
Osteoporosis 
-0.6 0.2 -2.680 0.007** 
History: 
Psychological Condition 
0.6 0.2 3.335 0.001** 
History: 
Chest Pain 
0.2 0.3 0.855 0.392 
ZIP-Level Median Income 
(per $10,000) 
0.2 0.0 7.625 <0.001*** 
Adjusted R-squared 0.06, Root Mean Squared Error 6.7 
Coefficients & Standard Errors Rounded to 1 Decimal (except as noted) 






Table 4.3: Regression Coefficients Predicting MDQ Change: Derived from Included 








Intercept -14.6 13.1 -1.115 0.265 
Initial MDQ 0.52 0.01 87.477 <0.001*** 
Initial VR12 – MCS 0.15 0.01 10.492 <0.001*** 
Initial VR12 – PCS 0.12 0.02 7.631 <0.001*** 
BMI: Quintile 2 0.1 0.3 0.226 0.821 
BMI: Quintile 3 0.0 0.3 0.076 0.939 
BMI: Quintile 4 0.3 0.3 1.025 0.305 
BMI: Quintile 5 -1.4 0.3 -4.143 <0.001*** 
BMI: Missing -0.7 0.3 -2.237 0.025* 
Age: Quintile 2 -0.9 0.3 -3.093 0.002** 
Age: Quintile 3 -1.5 0.3 -5.211 <0.001*** 
Age: Quintile 4 -1.8 0.3 -5.849 <0.001*** 
Age: Quintile 5 -1.9 0.3 -6.038 <0.001*** 
Condition ≥ 90 Days -1.7 0.3 -6.620 <0.001*** 
Sex (Male) 1.1 0.2 5.588 <0.001*** 
History: 
Bowel & Bladder Problems 
-1.9 0.3 -5.528 <0.001*** 
History: 
High Blood Pressure 
-0.4 0.2 -1.836 0.066 
History: 
Diabetes (Any) 
-1.1 0.3 -3.379 0.001** 
History: 
Allergy (Non-Latex) 
0.3 0.2 1.189 0.234 
History: 
Smoking 
-1.7 0.3 -6.041 <0.001*** 
History: 
Night Sweats &/or Pain 
-2.8 0.3 -10.697 <0.001*** 
History: 
Cancer 
0.6 0.4 1.521 0.128 
History: 
Metal Implants 
-2.3 0.3 -7.114 <0.001*** 
History: 
Groin Numbness 
-2.5 0.5 -4.655 <0.001*** 
History: 
Fracture 
-0.6 0.4 -1.597 0.110 
History: 
Arthritis (Any) 
-2.8 0.2 -12.328 <0.001*** 
History: 
Stroke 
-2.1 0.9 -2.405 0.016* 
History: 
Allergy – Latex 
-1.1 0.5 -2.351 0.019* 
History: 
Ringing in Ears 
-0.6 0.3 -1.874 0.061 
History: 
Infection 






-0.4 0.4 -0.893 0.372 
History: 
Blood Clot / 
Deep Vein Thrombosis 
1.1 0.6 1.778 0.075 
History: 
Kidney Condition 
-0.4 0.6 -0.639 0.523 
History: 
Sexual Dysfunction 
-2.1 0.5 -4.079 <0.001*** 
History: 
Seizures 
-3.3 0.8 -4.113 <0.001*** 
History: 
Pregnant 
-5.4 0.8 -7.190 <0.001*** 
History: 
Fever or Nausea 
-0.2 0.6 -0.435 0.664 
History: 
Double Vision 
-1.4 0.7 -1.992 0.046* 
History: 
Unexplained Weight Loss 
-2.1 1.0 -2.165 0.030* 
History: 
Pacemaker 
-0.5 1.3 -0.379 0.705 
History: 
Breathing Difficulties / 
Asthma 
-0.7 0.3 -2.608 0.009** 
History: 
Difficulty Swallowing 
-2.6 0.6 -4.028 <0.001*** 
History: 
Osteoporosis 
-0.3 0.5 -0.690 0.490 
History: 
Psychological Condition 
-1.7 0.4 -4.501 <0.001*** 
History: 
Chest Pain 
-1.4 0.5 -2.690 0.007** 
ZIP-Level Median Income 
(per $10,000) 
0.1 0.0 2.481 0.013* 
Adjusted R-squared 0.29, Root Mean Squared Error 13.0 
Coefficients, Confidence Intervals (CIs), and Errors Rounded to 1 Decimal (except as noted) 


















Discussion & Concluding Remarks
Study Summary 
The broad goals of these investigations were to use a single patient population 
from a large, unified physical therapy provider to 1) identify the influence of patient 
financial liability on visits and patient reported outcomes (PROs) and 2) analyze the 
samples of included and excluded patients to establish an understanding of the 
generalizability of the results to a broader patient population. An instrumental variable 
(IV) regression approach was used to analyze Research Question 1. The IV, insurance 
plan-level patient financial liability per visit, exhibited mediocre strength to differentiate 
a marginal subset of patients for whom visit count was influenced by their willingness 
and ability to pay for an additional physical therapy visit; however, the direction of the 
effect was counter to stated theory. This is likely related to the lack of control for 
individual-level socioeconomic status and plan structure. Recent evidence suggests that 
patients with higher socioeconomic status self-select to high deductible plans and/or 
plans that allow for health savings accounts as they are more comfortable taking on the 
risk associated with healthcare cost.47,70 Despite the findings and lack of significance 
observed in this study, there remains evidence in support of physical therapy as a low 
risk, low cost intervention for patients with LBP. Denninger et al52 identified a cost 
savings of nearly $1,600 per patient in the year following enrollment in a physical 




visit when compared against to those that followed the typical medical referral model that 
was deductible and coinsurance-based. An earlier physical therapy-first study by Mitchell 
and de Lissovoy90 identified similar cost savings of over $1200 per patient for patients 
that sought physical therapy first over those following the traditional medical referral 
path. Frogner et al91 identified lower out-of-pocket cost to the patient, lower probability 
of opioid and advanced imaging utilization, and less emergency department utilization in 
patients that saw a physical therapist for LBP as their first point of contact. Additional 
evidence from Garrity et al47 concluded that unrestricted direct access to physical therapy 
resulted in decreased health utilization and costs in patients with LBP. Finally, a 2019 
systematic review by Arnold et al92 observed consistently lower utilization of health 
services in patients that received early physical therapy for LBP relative to delayed 
physical therapy or usual medical care. While indirectly related, insurance plans that 
incentivize physical therapy (i.e., as described in Denninger et al52) might logically 
expect a larger number of patients to seek physical therapy services early or first, rather 
than delayed or not at all. While the results of Research Question 1 presented in Chapter 
3 may appear to run counter to these studies, it is likely a function of missing and 
unavailable patient information. Because individual level financial information likely 
drives healthcare decisions more than population-based socioeconomic status (i.e., ZIP-
level median income) and average insurance-level financial liability per physical therapy 
visit, our inability to control for individual socioeconomic status and health plan structure 






Generalizability and Limitations of Results 
The comparison of patient cohorts that were included and excluded from the 
primary study yielded few potentially clinically important differences. It was an expected 
finding that visits differed between cohorts because many in this cohort lacked a follow-
up MDQ, as the electronic health record prompts the physical therapy provider to seek 
follow-up outcomes at specified visit (often 10 visits) or chronological (often 30 days) 
increments. These patients lacking a follow-up MDQ might actually represent a 
“marginal” population of patients that fail to continue their intended course of physical 
therapy as a direct result of financial barriers. Unfortunately, we are left to compare their 
baseline information and the 2 “index” measures with those included to determine a level 
of generalizability to this group. Patient financial liability was only available on final 
adjudicated and paid claims—not those that were still being pursued and negotiated. 
Again, the patient population engaged in a lengthy collections process may further 
represent patients for whom insurance-level patient financial liability may influence their 
ability to fully participate in a physical therapy episode of care. 
Finally, we are left to consider the effect of unexplained variance on the 
generalizability of results. Available information explains less than 5% of the variability 
in visits. It is likely that other clinical, financial, behavioral, and/or belief-related factors 
that are currently unmeasured play a role in predicting visits and this unmeasured 
confounding is a threat to generalizability. Similarly, with 24% of the variance explained 
in the prediction of MDQ change, it is likely that some of these other unmeasured factors 




available information derived from these studies, we did not find any differences and are 
comfortable with the generalizability of results. 
Future Direction 
Prior to moving toward manuscript publication, it is important to seek “better” 
patient and insurance-level information. While individual socioeconomic status is likely a 
large contributor in patients’ ability or inability to participate in complete physical 
therapy episodes of care, a large, privately owned physical therapy provider will not 
likely ever collect this information on a large scale. The only remaining possible data 
refinement that can improve model performance and decreased unexplained variance is 
acquisition of specific plan structure. Consistent with recent findings, it is our belief that 
being able to control for information related to plan structure will significantly improve 
model performance for regression models predicting physical therapy visit count.47 
Related information including the use of capitation and/or requisite authorization would 
further optimize the prediction of physical therapy visit count. Finally, future research 
should further explore the interrelationship between personal factors, health insurance 
plan structure, utilization of non-pharmacological guideline adherent interventions 
(including physical therapy), and functional outcomes using a variety of research 
methods. It will be vital to better understand these relationships as healthcare and 
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